Results 31 to 40 of about 9,333,661 (382)

Inflammatory Markers Associated With Subclinical Coronary Artery Disease: The Multicenter AIDS Cohort Study. [PDF]

, 2016
BackgroundDespite evidence for higher risk of coronary artery disease among HIV+ individuals, the underlying mechanisms are not well understood. We investigated associations of inflammatory markers with subclinical coronary artery disease in 923 ...
Bahrami, Hossein, Budoff, Matthew, Haberlen, Sabina A, Ketlogetswe, Kerunne, Kingsley, Lawrence, McConnell, Michael V, Palella, Frank, Post, Wendy S, Rezaeian, Pantea, Tracy, Russell, Witt, Mallory D   +10 more
core   +2 more sources

Regulation of adipose tissue inflammation by interleukin 6

Proceedings of the National Academy of Sciences of the United States of America, 2020
Significance Chronic low-grade inflammation is a key driver of metabolic syndrome. This inflammatory response is mediated by immune-cell infiltration and the expression of inflammatory cytokines.
M. Han, Alexis White, R. Perry, J. Camporez, J. Hidalgo, G. Shulman, R. Davis   +6 more
semanticscholar   +1 more source

Interleukin-6 Promoter Haplotypes and Interleukin-6 Cytokine Responses [PDF]

Shock, 2003
Genetic variations contribute to differences in the inflammatory response and are markers for disease risk and outcomes. We studied three single-nucleotide polymorphisms (-597 G-->A, -572 G-->C, and -174 G-->C) in the IL-6 promoter to determine associations with ex vivo LPS-stimulated IL-6 production by leukocytes.
Grant E. O'Keefe, Dixie L. Peters-Hybki, Fernando A. Rivera-Chavez, Robert Barber   +3 more
openaire   +3 more sources

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update [PDF]

Annals of the Rheumatic Diseases, 2023
Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine.
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja A Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes WJ Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L Hyrich, Annamaria Iagnocco, John D Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S Smolen   +43 more
openaire   +10 more sources

Salivary Interleukin 6 and Sialic acid in Periodontitis

Brazilian Journal of Oral Sciences, 2018
Aim: Periodontitis is the major multi –factorial chronic infectious oral diseases in dentate people. Sialic acid regulates innate immunity response that release cytokines.
Jwan Ibrahim Jawzali
doaj   +1 more source

Fetal and early neonatal interleukin-6 response [PDF]

, 2015
In 1998, a systemic fetal cytokine response, defined as a plasma interleukin-6 (IL-6) value above 11 pg/mL, was reported to be a major independent risk factor for the subsequent development of neonatal morbid events even after adjustments for gestational
B. Resch, C. Chiesa, F. Natale, N. Hofer, OSBORN, John Frederick, PACIFICO, Lucia   +5 more
core   +1 more source

Cardiometabolic risk factors and their relationship with the interleukin-6 receptor gene polymorphism (rs2228145) in patients with hypertrophic cardiomyopathy

Российский кардиологический журнал, 2020
Aim. To analyze associations of interleukin-6 receptor gene (IL6R) polymorphism (rs2228145) with the clinical course characteristics of hypertrophic cardiomyopathy (HCM) in groups of patients with various cardiometabolic risk factorsMaterial and methods.
T. G. Bezhanishvili, A. Ya. Gudkova, V. G. Davydova, S. E. Andreeva, A. N. Krutikov, E. N. Semernin, B. N. Kudryavtsev, S. A. Pyko, A. A. Kostareva, E. N. Shlyakhto   +9 more
doaj   +1 more source

Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice [PDF]

, 2015
Duchenne muscular dystrophy (DMD) is characterized by progressive lethal muscle degeneration and chronic inflammatory response. The mdx mouse strain has served as the animal model for human DMD. However, while DMD patients undergo extensive necrosis, the
Berardinelli, Maria Grazia, Camilli, Carlotta, Catizone, Angela, De Benedetti, Fabrizio, Forcina, Laura, Musarò, Antonio, Nicoletti, Carmine, Pelosi, Laura, Rizzuto, Emanuele, Spelta, Elisa, Testa, Erika   +10 more
core   +2 more sources

Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome

European Respiratory Journal, 2020
The concept of coronavirus disease 2019 (COVID-19)-related cytokine storm syndrome (COVID-CSS) emerged early in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic to explain why some patients exposed to this virus become critically
Luke Y. C. Chen, R. Hoiland, S. Stukas, C. Wellington, M. Sekhon   +4 more
semanticscholar   +1 more source

ZNF580 – a brake on Interleukin-6 [PDF]

Journal of Inflammation, 2018
Zinc finger protein 580 (ZNF580) was reported to modulate angiogenesis, endothelial homeostasis and blood pressure control. ZNF580 regulated genes include VEGF-A and IL-8. However, it is unknown if ZNF580 could play a role during inflammation. The aim of this study was to find out if ZNF580 affects the expression of IL-6, if it occurs in monocytic ...
Kaj Nagorsen, Philipp Stenzel, Andreas Zakrzewicz, Jonathan Bernd, Janine Berkholz, Ulrike Leppert   +5 more
openaire   +4 more sources